Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome: Insights From ASET Pilot Studies.
| Autor: | Masuda S; Department of Cardiology, University of Galway, Galway, Ireland., Tanabe K; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan., Guimarães PO; Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.; Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Muramatsu T; Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan., Ozaki Y; Department of Cardiology, Fujita Health University Okazaki Medical Center, Okazaki, Japan., De Martino F; Department of Internal Medicine, Discipline of Cardiology, University of Triangulo Mineiro, Uberaba, Brazil., Kozuma K; Department of Cardiology, Teikyo University Hospital, Tokyo, Japan., Garg S; Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom.; Department of Medicine, University of Central Lancashire, Preston, United Kingdom., Kotoku N; Department of Cardiology, University of Galway, Galway, Ireland., Ninomiya K; Department of Cardiology, University of Galway, Galway, Ireland., Kageyama S; Department of Cardiology, University of Galway, Galway, Ireland., Lemos PA; Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Onuma Y; Department of Cardiology, University of Galway, Galway, Ireland., Serruys PW; Department of Cardiology, University of Galway, Galway, Ireland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JACC. Asia [JACC Asia] 2023 Dec 12; Vol. 4 (3), pp. 171-182. Date of Electronic Publication: 2023 Dec 12 (Print Publication: 2024). |
| DOI: | 10.1016/j.jacasi.2023.10.007 |
| Abstrakt: | Background: The ASET (Acetyl-Salicylic Elimination Trial) pilot studies recently investigated P2Y Objectives: This comparative analysis of the 2 ASET pilot studies aimed to summarize clinical outcomes and assess geographic and ethnic differences in baseline demographics and procedures. Methods: Patients undergoing successful platinum-chromium everolimus-eluting stent implantation for chronic coronary syndrome were included. Following the index PCI, patients received prasugrel monotherapy with a maintenance dose of 10 mg/day in Brazil and 3.75 mg/day in Japan. The primary ischemic endpoint was the composite of cardiac death, spontaneous target vessel myocardial infarction, or definite stent thrombosis. The primary bleeding endpoint was Bleeding Academic Research Consortium types 3 and 5 bleeding at up to 3 months. Results: Of 409 enrollments, 3-month follow-up was completed in 406 patients. Mean age was 64.3 ± 8.4 years, and 73% were men. Overall, post-TIMI flow grade 3 was achieved in 99.8%. Intravascular imaging for poststent optimization was used in 16.8% and 99.6% of treated lesions in Brazil and Japan, respectively. The primary ischemic and bleeding endpoints occurred in the same patient (0.2%). No stent thrombosis events occurred. Conclusions: Prasugrel monotherapy following PCI was safe and feasible in selected low-risk chronic coronary syndrome patients after optimal platinum-chromium everolimus-eluting stent implantation regardless of the ethnic and geographic differences in baseline demographics, procedures, and prasugrel dosage. Randomized controlled trials will be needed to compare P2Y Competing Interests: Dr Masuda has received a grant from Terumo Corporation outside the submitted work. Medical. Dr Tanabe has received honoraria from Boston Scientific and Daiichi-Sankyo. Dr Muramatsu has received honoraria from Boston Scientific Japan and Daiichi-Sankyo. Dr Ozaki has received a research grant from Takeda Pharma Ltd, Daiichi-Sankyo Company Ltd, and Terumo Corporation. Dr Kotoku has received a grant for studying overseas from the Fukuda Foundation for Medical Technology. Dr Kozuma has received honorarium for lectures and advisory board from Daiichi-Sankyo and Boston Scientific. Drs Serruys and Onuma have reported institutional grants from Heartflow Inc and GE. Dr Serruys has reported consultancy for Xeltis, SMT, Philips, Novartis, and Merillife outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2024 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|